CPAI vs. CNCR ETF Comparison

Comparison of Counterpoint Quantitative Equity ETF (CPAI) to Loncar Cancer Immunotherapy ETF (CNCR)
CPAI

Counterpoint Quantitative Equity ETF

CPAI Description

CPAI employs a quantitative, model-driven strategy that integrates quantitative analysis and machine learning insights to navigate diverse market conditions. The portfolio consists of at least 50 US-listed companies of any capitalization or ADRs. The selection process relies on advanced quantitative models leveraging machine learning technology, considering over 30 variables related to value, long-term reversal, momentum, profitability, investor sentiment, and stock price stability. Additionally, the Adviser backtests variable combinations considered to be supported by economic reasoning or investor behavioral biases. The models continually learn and adapt relationships between input variables and realized historic returns, updating during quarterly portfolio rebalances. Moreover, rebalancing ensures the portfolio aligns with the models' rankings, with adjustments made to limit sector exposure to 35% or less.

Grade (RS Rating)

Last Trade

$33.06

Average Daily Volume

5,402

Number of Holdings *

10

* may have additional holdings in another (foreign) market
CNCR

Loncar Cancer Immunotherapy ETF

CNCR Description ETF Series Solutions - Loncar Cancer Immunotherapy ETF is an exchange traded fund launched by ETF Series Solutions. The fund is co-managed by Exchange Traded Concepts, LLC and Vident Investment Advisory, LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating in the pharmaceutical or biotechnology sectors, including those companies identified as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. It invests in stocks of companies across all market capitalizations. The fund seeks to replicate the performance of the Loncar Cancer Immunotherapy Index, by investing in stocks of companies as per their weightings in the index. ETF Series Solutions - Loncar Cancer Immunotherapy ETF is domiciled in the United States.

Grade (RS Rating)

Last Trade

$14.73

Average Daily Volume

4,200

Number of Holdings *

67

* may have additional holdings in another (foreign) market
Performance
Period CPAI CNCR
30 Days 3.25% -2.32%
60 Days 9.98% 3.51%
90 Days 4.80% 11.89%
12 Months 40.02%
0 Overlapping Holdings
Symbol Grade Weight in CPAI Weight in CNCR Overlap
CPAI Overweight 10 Positions Relative to CNCR
Symbol Grade Weight
CVLT C 2.53%
MCY B 2.48%
PPC B 2.39%
WGS A 2.37%
THC C 2.36%
JXN A 2.36%
UNFI B 2.29%
COOP B 2.25%
MSI A 2.24%
TRGP B 2.23%
CPAI Underweight 67 Positions Relative to CNCR
Symbol Grade Weight
SMMT D -6.48%
GERN D -3.44%
ELVN B -2.87%
NRIX D -2.41%
IGMS C -2.2%
FHTX C -2.17%
ACRV D -2.0%
RVMD B -1.88%
JANX D -1.87%
TYRA C -1.87%
KYMR D -1.78%
NUVB F -1.76%
ERAS D -1.75%
ACLX C -1.74%
REPL B -1.74%
AURA C -1.71%
BNTX B -1.71%
NUVL B -1.7%
TSVT B -1.7%
EXEL B -1.64%
REGN D -1.6%
MRUS D -1.51%
BCYC D -1.47%
BPMC F -1.44%
DAWN D -1.41%
ITOS F -1.39%
IMRX D -1.39%
IMTX F -1.38%
HCM B -1.38%
CGEM F -1.38%
GLUE D -1.37%
MRK F -1.35%
BMY B -1.34%
KURA F -1.29%
XNCR D -1.29%
RLAY F -1.28%
STRO F -1.26%
IPHA F -1.23%
YMAB B -1.22%
RCUS F -1.21%
GMAB F -1.12%
SNDX F -1.11%
IDYA F -1.06%
SDGR F -1.04%
LEGN F -0.98%
ACET D -0.98%
IOVA F -0.96%
PGEN F -0.95%
SWTX F -0.93%
LYEL F -0.91%
RPTX D -0.91%
RXRX F -0.87%
AUTL F -0.86%
ALLO F -0.84%
ARVN F -0.76%
PRLD F -0.75%
KPTI D -0.73%
IMCR F -0.72%
FATE F -0.71%
BMEA D -0.69%
VOR F -0.63%
MRSN D -0.55%
CRBU F -0.5%
GNLX D -0.49%
ZNTL F -0.4%
RAPT F -0.29%
MGNX F -0.27%
Compare ETFs